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Abstract  
Background: OnabotulinumtoxinA injections improve upper limb spasticity after 
stroke but their effect on arm function remains uncertain.  
Objective: To determine whether a single treatment with OnabotulinumtoxinA 
injections combined with upper-limb physiotherapy improves grasp release 
compared to physiotherapy alone after stroke. Methods: 28 patients, at least one 
month post-stroke, were randomised to receive either OnabotulinumtoxinA or 
placebo injections to the affected upper limb followed by standardized upper-limb 
physiotherapy (10 sessions over four weeks). The primary outcome was time to 
release grasp during a functionally relevant standardized task. Secondary outcomes 
included measures of wrist and finger spasticity and strength using a customised 
servomotor, clinical assessments of stiffness (modified Ashworth Scale - MAS), arm 
function (Action Research Arm Test-ARAT, Nine Hole Peg Test), arm use (Arm 
Measure of Activity - ArMA), goal attainment scale (GAS) and quality of life (EQ5D).   
 
Results: There was no significant difference between treatment groups in grasp 
release time 5 weeks post injection (placebo median = 3.0s, treatment median = 
2.0s; t(24) = 1.20, p=0.24; treatment effect -0.44, 95% CI -1.19 to 0.31). None of the 
secondary measures passed significance after correcting for multiple comparisons. 
Both groups achieved their treatment goals (placebo=65%, treatment=71%), and 
made improvements on the ARAT (placebo +3, treatment +5) and in active wrist 
extension (placebo +9 degrees, treatment +11 degrees).  
 
Conclusions: In this group of stroke patients with mild to moderate spastic 
hemiparesis, a single treatment with OnabotulinumtoxinA did not augment the 
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improvements seen in grasp release time after a standardized upper-limb 
physiotherapy programme.   
 
Clinical trial registration: EudraCT 2009-009357-22 
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Introduction 
Upper-limb disability is problematic for many stroke survivors. Clinical and 
experimental observation suggest that disordered grasp release is a significant 
contributory factor. Although difficulties with grasp release have been shown to be 
primarily due to extensor weakness and impaired motor control,1,2 there is some 
evidence that persistent flexor activation may also contribute.2 In the clinical setting, 
rehabilitation specialists increasingly postulate that temporarily reducing finger flexor 
over activation could enhance interventions to improve hand function after stroke.   
Sustained or intermittent involuntary muscle activation after stroke is a 
manifestation of spasticity, as recently defined by Pandyan et al.3 Spasticity is 
common after stroke4,5 and its treatment is increasingly integrated in stroke 
rehabilitation and care. Systematic review provides strong evidence that Botulinum 
neurotoxin type A (OnabotulinumtoxinA) reduces spasticity and improves passive 
function; for example, easing opening of the hand for cleaning and skin care.6 
Observational studies without controls or blinding have shown some promising 
results in improving active function of the upper limb.7–9 However, effects have been 
variable and significant changes are yet to be shown in placebo randomised 
controlled trials.10–12 According to previous reviews, the lack of effect could reflect 
study limitations and recommendations were made that future research should 
measure change in specific active functional tasks or outcomes, and that an 
objective quantification of spasticity should be used.12–15  
PROMBIS (Predicting Outcomes and Measuring benefit of Botulinum therapy in 
Stroke) is an exploratory randomized, double-blind, placebo-controlled parallel-group 
trial to investigate the effect of OnabotulinumtoxinA on one such specific outcome: 
grasp-release time. We hypothesized that the active treatment group would 
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demonstrate a statistically significant improvement in grasp release time compared 
to the control group.  
Primary objective. To determine whether targeted OnabotulinumtoxinA injections 
(BOTOX®, Allergan Limited, Marlow, UK) combined with standardized physiotherapy 
treatment of the upper limb after stroke will reduce grasp release time, a quantitative 
measure of active upper limb function. 
 
Methods 
Study design. A parallel group double-blind randomised controlled trial (RCT) with 
subjects randomly allocated in a 1:1 ratio between treatment and placebo groups. 
Participants performed baseline assessment and were then given injections of either 
placebo or OnabotulinumtoxinA in week 0, followed by ten sessions of intensive 
standardized physiotherapy over four weeks.16 Outcomes were then re-assessed at 
weeks 5, 9 and 13. 
Standard protocol approvals, registrations, and patient consent. The trial was 
undertaken at The National Hospital for Neurology and Neurosurgery from 2009 to 
2014 and the protocol and all amendments approved by the local review board. 
Written informed consent was obtained from all participants at the screening 
assessment. The study is registered on the EU Clinical Trial Register (EudraCT: 
2009-009357-22) and is reported here in accordance with the CONSORT guidelines 
for reporting of RCTs.17 
Participants. Patients presenting to focal spasticity clinics at the National Hospital 
for Neurology and Neurosurgery were screened for eligibility by the multidisciplinary 
team (MDT) including members of the independent research team. Inclusion criteria 
were: 1) confirmed diagnosis of stroke more than one month previously; 2) 
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established focal finger or wrist spasticity that the MDT felt could be interfering with 
active grasp and release function and had the potential to benefit from treatment with 
OnabotulinumtoxinA (this included an assessment on whether the potential 
participant presented with sufficient residual strength and motor control for 
rehabilitation to be effective);  3) score of 2 or more in the modified Ashworth scale in 
the joints of interest and 4) ability to  transport the assessment cup to at least one of 
the target positions and release it at baseline. Exclusion criteria were: 
OnabotulinumtoxinA injections to any site within the previous three months; contra-
indications to OnabotulinumtoxinA; fixed contracture in the upper limb; additional 
neurological impairment not related to stroke; uncontrolled upper limb pain; cognitive 
impairment preventing informed consent or the ability to follow task instructions. 
Participants were not required to be naïve to OnabotulinumtoxinA treatment. 
Randomization and blinding. Randomization was performed by an additional 
statistician prior to trial commencement using a block randomisation process to 
ensure equal numbers in each treatment arm (the trial statistician was blind to group 
allocation). Details of the blinding procedures including allocation concealment are 
provided in appendix e-1 (supplementary materials). 
Intervention. Drug intervention: Injection sites were identified with standard 
neurophysiological technique (electromyography and electrical stimulation) using a 
portable handheld device (Clavis; Medtronic, Minneapolis, USA)18. The doses and 
distribution of the injections were guided by the clinical and neurophysiological 
evaluation (including the magnitude of the audible stretch response and degree of 
resting muscle over-activity) as per standard clinical practice.  
Allergan BotoxTM, diluted as 100 units in 2 mls of saline, or a saline placebo was 
injected through a fine bore EMG needle electrode into the muscles identified by the 
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multidisciplinary assessment as likely to be hindering function. Treatment and 
placebo solutions looked identical and were reconstituted out of sight of the injecting 
doctor, treating physiotherapist, and the participant.  
 
Physiotherapy intervention: The standardized physiotherapy intervention has 
previously been described in detail16. The original protocol consisted of daily 
sessions over 10 consecutive working days. For this study, it was modified to occur 
over 4 weeks to focus training during the peak action of the drug and reflect current 
clinical practice of outpatient therapy provision. The total session time ranged from 
45 minutes up to 1.5 hours to accommodate each patient’s need to complete the 
tasks, rest and stretch without affecting the overall intensity (repetitions) of the 
therapy.  
In summary, the protocol included both strength training (three different muscle 
groups) and functional task practice (three different tasks). Strength training 
consisted of three sets of 10 repetitions of wrist extension, finger extension and grip 
strength at 60–80% of maximal isometric voluntary contraction measured in mid-
range and was recalibrated every 3 training days.  
Functional training tasks were chosen by the subject relevant to their personal 
treatment goals. The intervention was tailored to the individual’s impairment level so 
that the intensity of intervention was standardized despite differing impairment levels 
at enrolment.  
Participants were encouraged to stretch whenever needed throughout the strength 
and functional training.  
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Primary outcome variable We used a functionally relevant grasp-release task 
that measured the time taken to release grasp after moving an instrumented cup to a 
target. Grasp release timing data was calculated from first contact of the cup on the 
target until all digits were released from the cup. All electronic data were collected in 
a custom software programme (LabVIEW, National Instruments Corporation, Austin, 
Texas) then exported and further analysed with MATLAB scripts (The MathWorks 
Inc, Massachusetts, USA).  
The targets were spread over 4 positions (2 in near space at 50% of arm length 
and 2 in far space at 90% of arm length) and two heights (low, at two cm above the 
table surface, and high, which was individually adjusted so that the subject required 
90 degrees of shoulder flexion to place the ulnar border of their hand on the target 
surface). Test-retest variability varied from excellent (in the near and low target, ICC 
0.8) to moderate (in the low far target, ICC 0.54).19 The participants could have 
assistance to place the cup into the hand but were required to be able to transport 
the cup to at least one target and release it unassisted. The cup weighed 300g and 
measured 124mm in height, with a base diameter of 58mm and top diameter of 
88mm. For more details see Appendix e-1 (supplementary materials). 
 
Secondary outcome variables Reliable measurement of spasticity remains 
controversial.3,20 Spasticity is defined as ‘‘disordered sensori-motor control, resulting 
from an upper motor neurone lesion, presenting as intermittent or sustained 
involuntary activation of muscles’’.3 We employed the modified Ashworth scale 
(MAS)21 as it has been widely used in previous studies and would allow for 
comparisons. The MAS was converted to a 6-point score from 0 to 5. However, as 
the Modified Ashworth scale assesses overall passive stiffness22 and has been 
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shown to be a subjective measure21,22 a servomotor (Kollmorgen D062M Direct 
Drive) was used to measure spasticity objectively. The motor was programmed to 
measure torque in response to slow and fast passive movements. In healthy control 
subjects there is no significant difference between these measurements.19 In people 
with upper motor neuron lesions such as stroke, involuntary activation of the flexor 
muscles in response to the fast stretch of the motor (spasticity) can be objectively 
quantified as an increase in torque. The technique provides quantification of stretch 
reflex mediated activity which is proportional to and correlates with the size of the 
EMG response in people with Upper Motor Neuron Syndrome.23  
The servomotor held the subjects’ arm firmly in position with the axis of either the 
metacarpophalangeal (MCP) joints or the wrist joint aligned to the axis of the motor. 
Wrist stretches started in 10 degrees of flexion moving through 20 degrees to 10 
degrees extension. Finger stretches started in 45 degrees flexion, moving back 20 
degrees. The fingers were measured together as the apparatus was not capable of 
measuring individual fingers. Subjects were instructed to relax and let the motor 
move their arm without resistance. Passive stiffness of the flexor muscles was 
measured by recording mean torque over 5 slow stretches (20 deg at 6 deg.s-1) 
while EMG recordings confirmed that the muscle was not activated. There was no 
reflex activity at this slow speed and therefore the measure represents soft tissue 
stiffness without the reflex (spasticity) component. Total stiffness, which includes 
passive and reflex components, was measured by recording mean torque over 5 fast 
stretches (20 deg at 300 deg.s-1) while EMG recordings identified and quantified the 
presence and duration of reflex response (spasticity). For more details of the 
methodology see Appendix e-1 (supplementary materials).  
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Isometric wrist and finger flexion and extension strengths were measured against 
the stationary servomotor with joints at zero degrees. Grip strength was measured 
by dynamometer. Wrist and finger range of movement was measured using a 
standard goniometer and positioning. 
Functional tests comprised the Nine Hole Peg Test24 and the Action Research Arm 
Test (ARAT)25. The Arm Measure of Activity (ArMA)26 and EQ5D28 quality of life 
measure were completed. The ArMA is a self-reported functional scale with passive 
and active subscales that use a Likert scoring system between 0 (no difficulty) and 4 
(unable to do task).  
Finally, two personalised functional goals, including a grasp release goal, were 
also agreed with each participant. 
 
Statistical analysis. Primary outcome analysis was performed using Analysis of 
Covariance (ANCOVA). Week 5 measurements were used as the outcome measure, 
with baseline score as the covariate, and a complete case analysis performed. All 
subjects completed baseline and immediate outcome measurement sessions. Data 
required log transformation to achieve normal distribution prior to analysis. Missing 
values, where subjects were unable to complete the grasp release task at all target 
positions, were imputed as per trial protocol using the maximum grasp release time 
recorded in the dataset at that given time point. The baseline adjusted mean 
difference between groups was reported along with corresponding 95% confidence 
interval.  
Secondary analyses analysed combined data from all time periods. Generalised 
estimating equation (GEE) models were fitted to account for clustering of patients 
over time. Baseline values were included as one of the covariates in the model. 
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 Assumptions were checked, and where they were not met, data transformation 
was performed prior to analysis. Where data transformation was not possible, a non-
parametric test was used. 
 
Results 
Participants. Twenty-eight participants were recruited in total and randomized, 14 
to each arm of the trial. The flow of participants is shown in figure 1 (CONSORT 
diagram). Baseline characteristics are presented in table 1. There were no significant 
differences between the groups at baseline. Most participants had experience of 
OnabotulinumtoxinA treatment (not within the preceding three months) but none had 
previously received an intensive upper-limb specific intervention. The treatment 
group received a total of 115 units (range 40 - 190) and a median of 5 muscles were 
injected per participant (range 1 to 8).  The placebo group received 151 units (range 
55 - 290) with a median of 7 muscles injected per participant (range 4 - 12). Table 4 
gives a summary of the number of participants injected broken down by muscle. 
Please see e-Table 1 in the supplementary information for a more detailed 
breakdown of dose and muscles injected per participant.  
Safety. There were two unrelated serious adverse events during the trial. One 
occurred after consent but prior to administration of the trial drug (ocular migraine, 
treated initially as a possible ocular TIA) and the other occurred 4 months after 
injection (kidney vasculitis). Neither subject was withdrawn. The emergency 
unblinding procedure was not used. Minor adverse reactions were reported as 
expected (detail in supplementary material Table e-2). 
Primary outcome. There was no statistically significant difference in grasp 
release time in all four positions between treatment groups at follow-up at week 5, 
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(Placebo median = 3.0s, treatment median = 2.0s; t(24) = 1.20, P=0.24). Treatment 
effect was -0.44, and the 95% confidence interval -1.19 to 0.31. Within group median 
change for placebo was -606ms and treatment -1200ms. This finding remained true 
even when the low-near position (easiest target to reach) was considered in isolation 
(Placebo median = 4.0s, treatment median = 2.0s; t(24) = 0.65, p=0.52; treatment 
effect -0.30 CI -1.27 to 0.67). Within group median change for placebo was -423ms 
and treatment -2364ms.See table 2 and figure 2.  
Secondary outcomes. There was no significant difference between groups on 
any of the secondary outcomes after correction for multiple comparisons (see table 
3). 
The Modified Ashworth group sum of scores decreased a total of 3 and 11 levels 
respectively for wrist and finger flexors in the placebo group, versus 11 and 19 in the 
active treatment group. Physiological measures of stiffness (slow motor) were not 
significantly different between groups in the wrist or fingers (for detailed values see 
Table 3); there was similarly no group difference on change in spasticity measures 
(fast motor) for either of the joints tested.  
Wrist and finger extension strength improved with no significant difference between 
groups (placebo +0.04NM and +0.05Nm; treatment +0.31Nm and +0.37Nm 
respectively). Extrinsic grip strength was maintained in the treatment group at 5 
weeks despite the weakening effect of OnabotulinumtoxinA injections (see table 3). 
Active wrist extension range of movement improved in both groups (placebo +9 
degrees, treatment +11 degrees), as did active finger extension range of movement 
(placebo +1.96 degrees, treatment +11.65 degrees). Both groups also achieved 
treatment goals (placebo 65%, active 71%), and improved on the ARAT (placebo +3, 
treatment +5), and the ArMA active subsection ( -1.0 in the placebo group versus -
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7.5 in the active treatment group). There was no change in either group for the 9HPT 
or the EQ5D. 
 
Discussion 
In this randomized placebo-controlled proof-of-concept trial, clinically and 
physiologically measured hypertonia decreased and function improved regardless of 
whether participants received active treatment with OnabotulinumtoxinA or placebo. 
There was no statistically significant difference between the OnabotulinumtoxinA and 
placebo groups on any measure of impairment, functional outcome or goal 
attainment. Although all measures were in favor of the OnabotulinumtoxinA group, 
this was not statistically significant.  
Although previous botulinum toxin studies have shown a significant reduction in 
spasticity measures,12,13 thus far translation to improvement in active function has 
not been clearly shown.12,13,27 Despite that, clinicians often propose 
OnabotulinumtoxinA injections to temporarily weaken overactive flexors and give a 
‘window of opportunity’ for active physiotherapy to strengthen extensor muscles and 
improve hand function. This treatment approach requires residual extensor strength 
and some level of voluntary control over the extensors in order to strengthen and 
train grasp release function. In this trial, we wanted to test this physiologically 
plausible principle using a scientifically robust but also pragmatic design. We opted 
for a relevant quantitative variable (grasp release time) as our primary outcome and 
we included physiological measures of spasticity, as recently recommended for new 
trials in this area.14,15 Moreover, this is the first study to use a standardized 
physiotherapy program. Our results did not support our hypothesis; in other words, a 
single treatment with OnabotulinumtoxinA group targeting the wrist and finger flexors 
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does not seem to offer additional improvement in grasp release after 4 weeks of a 
targeted physiotherapy intervention when compared to a placebo group.  
We acknowledge that the current study with its relatively small sample size does 
not provide a definitive answer on the usefulness of OnabotulinumtoxinA as an 
adjunct to improve active function in stroke patients with upper limb spasticity. A 
recent review has also shown no effect on active function at immediate outcome.27 
However, the authors acknowledge several limitations including the fact that 
adjuvant treatment may help optimize voluntary control, which was not controlled for 
in the included studies (16 out of 35 studies had no adjuvant treatment, quality and 
standardization of adjuvant therapy was unclear in the others). They also 
acknowledge that there was insufficient evidence for effects at a functional level and 
that the diversity of clinical measures used may have contributed to this. Our study 
has attempted to address some of these issues with standardized adjuvant therapy 
and the attempt to target and accurately measure one important functional activity 
(grasp release) that might be expected to benefit.  
A few other points merit discussion. In contrast with previous studies,12,13 clinical 
spasticity measures (MAS) did not differ between the groups. The same was true for 
the servomotor measures that are more likely to measure spasticity rather than 
overall stiffness. This lack of difference may, in part, be related to the adjuvant 
standardized physiotherapy regime employed in this study, as more than half of 
participants in Gracies et al12 were not receiving any therapy;  in others, patients 
received unspecified and non-standardized interventions, introducing a potential 
confounder into that data.13,28 It is also possible that the population investigated here, 
who were required to be able to complete a grasp release task for inclusion, 
represent a less severely impaired sample than the Gracies et al study.12 Patients 
PROMBIS RCT 
 
 
with more severe spasticity, i.e. unable to extend their fingers enough at baseline, 
may have shown better spasticity outcomes after the injections, but whether that 
would have translated to functional gains is debatable. As shown for other 
interventions,29 response is more likely when patients have baseline voluntary 
activity, particularly active finger extension. Indeed both groups did improve in 
strength and arm function measures, arguably due to the physiotherapy intervention. 
Whether this represents a ceiling effect or simply highlights that strength and motor 
control are stronger modifiers of outcome than spasticity in this group of patients 
cannot be answered from our current study. A different study design including 
patients with variable impairments as well as a considerably longer intervention 
could address that in the future.  
Another potential problem is the fact that patients were invited to enter if they were 
at least 1 month post stroke with no upper limit; this was again a pragmatic 
representation of the population referred to spasticity services. The vast majority of 
the patients were at least 6 months post stroke at enrollment (only one patient in the 
placebo group was enrolled at 3 months), which is the accepted cut-off point for 
chronic stroke and thus heterogeneity associated with plasticity related recovery 
should be minimal.  
In this study we have implemented a single treatment with OnabotulinumtoxinA 
and 4 weeks of standardized therapy and all our patients improved. It is possible that 
2 or more cycles of OnabotulinumtoxinA treatment could be more effective as some 
recent observational studies have suggested30,31 by consolidating the effects on 
spasticity and/or allowing more opportunity for retraining. The history of previous 
OnabotulinumtoxinA injections was not addressed in this study but may also have 
had potential to influence the outcome.  
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The intensity of physiotherapy is another important factor. We have opted for a 
pragmatic physiotherapy intervention but longer and more intensive therapy may 
have yielded better results. Looking from the opposite angle, one wonders if 
OnabotulinumtoxinA treatment without the same level of physiotherapy intervention 
(as often happens in clinical practice) may have shown stronger effects of the toxin 
per se and be more relevant to the current reality in stroke rehabilitation.  Finally, we 
have investigated a specific functional outcome aiming to address a common clinical 
question for chronic stroke patients with moderate to mild spasticity and our results 
were in line with those using more traditional functional outcome measures (e.g. 
ARAT); it is conceivable that another parameter may prove more responsive or 
sensitive to change. The slightly higher test-retest variability associated with far 
targets during the grasp release task suggests more cautious interpretation of this 
specific subset of results. 
We selected predominantly distal injection sites. In some cases proximal spasticity 
might have contributed to difficulty in the grasp release task. If participants were 
struggling with the reach part of the task, as many did, the additional effort could 
have made grasp release even more challenging. Targeting additional, including 
more proximal, targets thought clinically to be interfering with function may prove a 
better model for future trials.12,31,32 Likewise the measures of impairment gathered 
here (stiffness, spasticity, and muscle strength) have all been recorded in non-
functional laboratory conditions, different to those encountered during activities of 
daily living. Functional use of the arm and hand often involves reaching out and 
requires proximal muscle activity to take the weight of the arm or stabilise it in space. 
This effort could alter the impact of the impairment.33,34  
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Muscle stiffness and spasticity in the fingers were measured in mid-range to 
prevent contractures or tightness at end of range from interfering with measurement. 
Other studies though have tested throughout the available range and this could 
represent a more accurate measurement of stiffness within the functional range of 
movement35,36; this becomes even more important as the interval from the stroke 
increases.37 Accurate measurement of spasticity remains a challenge3,20 and 
requires careful consideration when used for patient selection or interpretation of 
functional change in research studies.3 
Conclusion 
In this group of stroke patients, addition of a single treatment with 
OnabotulinumtoxinA injection(s) aiming to reduce spasticity in the forearm flexors, 
was not significantly better than physiotherapy alone in improving grasp release time 
or other active functional outcomes.   
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Table 1: baseline patient demographics 
Variable Group   
All subjects Treatment Placebo 
Sex Male 19 9 10 
Female 9 5 4 
Age (years) Mean 49 50 48 
St Dev 16 18 14 
Range 18-82 21-82 18-68 
Time since stroke  
(months) 
Mean 66 83 50 
St Dev 92 118 46 
Range 3-456 7-456 3-145 
Stroke type Haemorrhage 10 (35.7%) 4 (28.6%) 6 (42.9%) 
Infarction 16 (57.1%) 10 (71.4%) 6 (42.9%) 
Both 1 (3.6%) 0 (0%) 1 (7.1%) 
Unknown 1 (3.6%) 0 (0%) 1 (7.1%) 
Stroke location Cortical 10 (35.7%) 5 (35.7%) 5 (35.7%) 
Subcortical 8 (28.6%) 6 (42.9%) 2 (14.3%) 
Both 2 (7.1%) 1 (7.1%) 1 (7.1%) 
Unknown 8 (28.6%) 2 (14.3%) 6 (42.9%) 
Barthel score Mean 92 90 94.6 
St Dev 9 11.6 4.6 
Range 65-100 65-100 85-100 
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Table 2: treatment effects on primary outcomes 
 Baseline  5 weeks  Mean change from baseline Significance 
Primary outcomes Treatment Placebo Treatment  Placebo  Treatment  Placebo  p value 
Mean grasp release all 4 positions (ms) 7089 (10326.81) 9100 (12394.31) 7285 (15361.01) 11478 (16108.19) +196  +2378 0.24 
Mean Grasp release (near and low) (ms) 8735 (11295.79) 9061 (11302.19) 7613 (15284.44) 10200 (15367.63) -1122  +1139  0.52 
 
Values are mean (SD) unless otherwise indicated, significance levels were p<0.05 for primary outcomes  
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Table 3: treatment effects on secondary outcomes 
 Baseline  5 weeks  Mean change from baseline Significance 
Secondary outcomes Treatment Placebo Treatment  Placebo  Treatment  Placebo  p value 
Wrist stiffness (slow : fast) 
(Nm.deg-1) 
0.03 : 0.052 
(0.016 : 0.02) 
0.036 : 0.072 
(0.024 : 0.041) 
0.037 : 0.052 
(0.017 : 0.019) 
0.034 : 0.056 
(0.029 : 0.033) 
+0.007 : 0.0 -0.02 : -0.016 0.783 : 0.583 
Finger stiffness (slow : fast) 
 (Nm.deg-1) 
0.042 : 0.043 
(0.027: 0.014) 
0.02 : 0.023 
(0.014 :0.005) 
0.026 : 0.029 
(0.021 : 0.02) 
0.023 : 0.026 
(0.028 : 0.021) 
+0.006 : -0.014 +0.003 : +0.003 0.067 : 0.046 
MAS wrist flexors (group sum of scores) 32 35 21 32 -11 -3 N/A 
MAS finger flexors (group sum of scores) 33 30 14 19 -19 -11 N/A 
Wrist extensor strength (Nm) 2.29 (2.21) 1.34 (1.24) 2.60 (2.40) 1.38 (1.25) 0.31 0.04 0.221 
Finger extensor strength (Nm) 0.43 (0.55) 0.51 (0.42) 0.80 (0.97) 0.56 (0.43) 0.37 0.05 0.884 
Grip strength (N) 109.33 83.72 110.53 104.53 1.00 20.81 0.486 
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Wrist extension ROM (passive : active)  
(degrees of motion) 
-62.0 : -32.15        
(19.30 : 26.68) 
-57.93 : -28.64          
(20.5 :20.20) 
-68.69 : -42.92         
(22.75 :16.61) 
-62.0 : -37.85              
(21.80 : 18.51) 
-6.69 : -10.77 -4.07 : -9.21 0.454 : 0.198 
Wrist flexion ROM (passive : active) 
(degrees of motion) 
66.43 : 45.46 
(19.2 : 13.94) 
77.93 : 52.0 
(18.47 : 16.38) 
71.54 : 44.92 
(22.26 : 15.88) 
74.0 : 52.0 
(15.79 : 19.02) 
+5.11 : -0.54 -3.93 : +7.08 0.101 : 0.121 
Finger extension ROM (passive : active) 
(degrees of motion) 
-29.14 : 25.73 
(26.52 : 26.76) 
-53 : 6.67 
(24.74 : 37.61) 
-39.58 : 14.08 
(26.83 : 25.13) 
-53.5 : 4.71 
(18.78 : 27.94) 
-10.44 : -11.65 -0.5 : -1.96 0.025 : 0.178 
Finger flexion ROM (passive : active) 
(degrees of motion) 
92.79 : 77.57 
(8.23 : 10.17) 
96.07 : 75.93 
(10.02 : 16.34) 
94.0 : 79.08 
(6.71: 15.27) 
94.5 : 79.71 
( 6.52 : 16.91) 
+1.21 : +1.51 -1.57 : +3.78 0.504 : 0.644 
NHPT  
(pegs per second) 
0.04 (0.09) 0.03 (0.07) 0.04 (0.1) 0.03 (0.08) 0 0 0.345 
Action Research Arm Test (ARAT) 
(range 0-57, 57= full function) 
24.14 (0.80) 23.43 (9.97) 29.23 (9.76) 25.57 (10.38) 5.09 2.14 0.480 
ArMA passive  
(range 0-28, 0=full function) 
6.50 (2.93) 7.50 (4.31) 6.00 (3.77) 8.50 (3.95) -0.5 +1.0 0.250 
ArmA active  
(range 0-52, 0=full function) 
41.00 (7.55) 38.50 (6.09) 33.50 (10.47) 37.50 (11.3) -7.50 -1.0 0.979 
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GAS: Goal 1  
(range -2 to +2)* 
-1 (0) -1 (0) 1.77 (0.6) 1.64 (0.63) +2.77 +2.64 N/A 
GAS: Goal 2  
(range -2 to +2)* 
-1 (0) -1 (0) 2.23 (0.83) 2.64 (0.84) +3.23 +3.64 N/A 
EQ5D  
(range  
 
0.62 (0.14) 0.637 (0.17) 0.61 (0.16) 0.68 (0.18) -0.01 + 0.043 0.225 
Values are mean (SD) unless otherwise indicated, significance levels were p<0.001 for secondary outcomes (adjusted for multiple 
comparisons). Key: Stiffness slow = passive stiffness of soft tissue with no reflex component measured with the motor at 6 
degrees/second, Stiffness fast = measures the reflex component (spasticity) with the motor at 300 degrees/second, Nm.deg-1 = 
Newton metres per degree,  MAS= Modified Ashworth Scale converted to a six point score (range 0 to 5),  Nm = Newton Metre, N = 
Newtons, ROM = range of movement;  extension movements are represented by negative numbers and a negative mean change 
represents an improvement in range, flexion movements are represented by positive numbers and a positive mean change 
represents an improvement in range; *GAS = Goal Attainment Score – a score of 0 or above indicates that the goal was achieved 
as planned 
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 Treatment n=14 Placebo n=14 Total n=28 
FDS 11 14 25 
FDP 1 2 3 
FPL 3 6 9 
FPB 0 1 1 
FCR 9 10 19 
FCU 7 9 16 
ECR 0 1 1 
ECU 0 1 1 
Lumbricals 4 2 6 
Pronator Teres 2 4 6 
Biceps 0 2 2 
Adductor Policis 0 1 1 
Thenar Eminance 0 1 1 
 
Table 4:  count of number of subjects injected for each muscle 
Key: FDS = flexor digitorum superficialis; FDP = flexor digitorum profundus; FCR = 
flexor carpi radialis; FCU flexor carpi ulnaris; ECR = extensor carpi radialis; ECU = 
extensor carpi ulnaris; FPL = flexor policis longus; FPB = flexor policis brevis. 
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Figures 
Uploaded as separate TIF files as required by journal. Labels and legends: 
Figure 1: Consort diagram 
Figure 2: Time taken to release grasp (mean +/- SEM) 
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